SFBC Acquires Anapharm

Miami-based SFBC International, Inc., a contract research organization to the pharmaceutical and biotechnology industries, acquired Quebec City-based Anapharm Inc.’s shares for approximately $48 million on March 18, 2002. The acquisition makes SFBC the largest phase I/II contract research organization in North America. In return for 100 per cent of Anapharm’s issued and outstanding shares, SFBC paid approximately $50 million in a combination of cash and SFBC common stock. The selling shareholders included Sofinov Société Financière d’Innovation Inc. and Anapharm’s angel investors and founders.
In Canada SFBC was represented by Osler, Hoskin & Harcourt LLP in Montreal, with a team led by Shahir Guindi and including Frédéric Dionne, Jean-Sébastien Lamoureux and Andrew Scipio del Campo (corporate), Martine Trudeau (securities) and François Auger and Geneviève Lille (tax). Michael Harris and Bradley Eavenson of Harris & Gilbert in Florida acted as U.S. counsel to SFBC.
Anapharm and its selling shareholders were represented by Desjardins Ducharme Stein Monast, with a team led by Charles Gagnon and including Kathleen Sauvé and Odette St-Laurent. Sofinov was also represented by in-house counsel Julie Tremblay. PricewaterhouseCoopers Securities Inc. acted as financial advisors to the selling shareholders.


Shahir Guindi Martin Roy Geneviève Lille Martine Trudeau François Auger Benjamin J. Greenberg Charles G. Gagnon Andrew Scipio del Campo


Osler, Hoskin & Harcourt LLP Stein Monast L.L.P. PwC Canada